Document Classification

Section Type: RESULTS

Text: The 10 patients who underwent supplementation with dexrazoxane exhibited a significant reduction of QT dispersion (67. 4 + / - 8. 1 vs. 49. 5 + / - 4. 2 ms, P < 0. 001) and QTc dispersion (71. 2 + / -. 7 vs. 51. 4 + / - 4. 3 ms, P < 0. 001), while the 10 patients not supplemented with dexrazoxane did not (QT dispersion : 69. 3 + / - 7. 6 vs. 64. 2 + / - 6. 9 ms ; QTc dispersion : 72. 8 + / - 8. 1 vs. 67. 3 + / - 7. 2 ms, ns).